First ever seaplane to fly in India today, Modi to be 1st passenger

New Delhi, Feb 8: A 26-year-old woman sub-inspector (SI) of the Delhi Police was shot dead near Rohini East Metro station on Friday night, officials said.

The SI, Preeti Ahlawat, was posted in Patparganj Industrial Area Police Station, police said.

A call about the incident was received around 9.30 pm, they said, adding she received gunshot wounds on her head.

"We have identified the suspects and CCTV footage of the area has been collected," said SD Mishra, Additional Commissioner of Police (Rohini).

Three empty cartridges were found from the spot, the officer said, adding a case has been registered and a probe is on.

Personal enmity is suspected to be the reason behind the killing, the officer said.

Ahlawat joined the Delhi Police in 2018.

New Delhi, May 25: India witnessed the highest ever spike of 6,977 positive cases in the last 24 hours, taking the total number of COVID-19 to 1,38,845, according to the Union Ministry of Health and Family Welfare.

India is now among the top 10 countries in the world regarding the total number of COVID-19 cases.

With 154 deaths reported in the last 24 hours, the total number of deaths due to COVID-19 now stands at 4,021 in the country.

Out of the total number of cases, 77,103 are active cases and 57,721 have been cured/discharged/migrated.

Maharashtra continues to remain the worst affected state with 50,231 COVID-19 cases, followed by Tamil Nadu (16,277), Gujarat (14,056) and Delhi (13,418).

The fourth phase of the nationwide lockdown imposed as a precautionary measure to contain the spread of COVID-19 is scheduled to end on May 31.

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.